Previous 10 | Next 10 |
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
CAMBRIDGE, Mass., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
Mersana Therapeutics, Inc. (MRSN) Q2 2019 Earnings Conference Call August 08, 2019, 08:00 ET Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Dirk Huebner - Chief Medical Offic...
Mersana Therapeutics (NASDAQ: MRSN ): Q2 GAAP EPS of -$0.36 beats by $0.02 . More news on: Mersana Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Patient Dosing in XMT-1536 Phase 1 Expansion Study Expected to Commence in Third Quarter 2019 Ended Second Quarter 2019 with $128 Million in Cash CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical compan...
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
Mersana Therapeutics (NASDAQ: MRSN ) appoints Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy. More news on: Mersana Therapeutics, Inc., Healthcare stocks news, Read more ...
Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN),...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...